NCT01259804

Study of Tolerance to Oral Peanut

Efficacy and Safety of High-dose Peanut Oral Immunotherapy With Factors Predicting Outcome

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Cambridge University Hospitals NHS Foundation Trust · Academic / Other
• Sex: All
• Age: 7 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

Open pilot study of peanut oral immunotherapy in 22 children with peanut allergy

Detailed description

Background Peanut allergy is severe and rarely resolves. Objective To test the efficacy and safety of a new oral immunotherapy protocol for peanut allergy. Method 22 peanut-allergic children will undergo oral challenge. Oral immunotherapy will be administered by gradual updosing with 2-weekly increments (8-38w) to 800mg protein (5 peanuts/day) followed by 30-weeks maintenance. Oral challenge will be repeated after 6 and 30 weeks maintenance.

Conditions

• Peanut Allergy

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Peanut oral immunotherapy	Daily doses of peanut flour

Timeline

• Start date: 2008-01-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2010-12-14
• Last updated: 2015-01-14

Locations

1 site across 1 country: United Kingdom